AdvanTIG-206
Recruiting
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
Beigene Study ID 
AdvanTIG-206
ClinicalTrials.gov ID
Sex:
All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Sex:
All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL